JP2020500931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500931A5 JP2020500931A5 JP2019548533A JP2019548533A JP2020500931A5 JP 2020500931 A5 JP2020500931 A5 JP 2020500931A5 JP 2019548533 A JP2019548533 A JP 2019548533A JP 2019548533 A JP2019548533 A JP 2019548533A JP 2020500931 A5 JP2020500931 A5 JP 2020500931A5
- Authority
- JP
- Japan
- Prior art keywords
- sepiapterin
- free base
- ray diffraction
- crystal form
- diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012458 free base Substances 0.000 claims 24
- 238000002441 X-ray diffraction Methods 0.000 claims 22
- 239000013078 crystal Substances 0.000 claims 19
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 claims 18
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 claims 16
- 229940126478 sepiapterin Drugs 0.000 claims 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000011252 Phenylketonuria Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102100031226 Alkylglycerol monooxygenase Human genes 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000033996 Autosomal recessive dopa-responsive dystonia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 102100034108 DnaJ homolog subfamily C member 12 Human genes 0.000 claims 1
- 208000013036 Dopa-responsive dystonia due to sepiapterin reductase deficiency Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000011370 GTP cyclohydrolase I deficiency Diseases 0.000 claims 1
- 208000011374 GTP cyclohydrolase I deficiency with hyperphenylalaninemia Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101000870234 Homo sapiens DnaJ homolog subfamily C member 12 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010069116 Tetrahydrobiopterin deficiency Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 108010043705 glyceryl-ether monooxygenase Proteins 0.000 claims 1
- 208000009322 hypertrophic pyloric stenosis Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000001195 sepiapterin reductase deficiency Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 208000015573 tyrosine hydroxylase deficiency Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427686P | 2016-11-29 | 2016-11-29 | |
| US62/427,686 | 2016-11-29 | ||
| PCT/US2017/063515 WO2018102314A1 (en) | 2016-11-29 | 2017-11-28 | Polymorphic form of sepiapterin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500931A JP2020500931A (ja) | 2020-01-16 |
| JP2020500931A5 true JP2020500931A5 (https=) | 2021-01-14 |
| JP7148532B2 JP7148532B2 (ja) | 2022-10-05 |
Family
ID=62241955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548533A Active JP7148532B2 (ja) | 2016-11-29 | 2017-11-28 | セピプテリンの多形 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11130760B2 (https=) |
| EP (1) | EP3548487A4 (https=) |
| JP (1) | JP7148532B2 (https=) |
| CN (1) | CN110312721A (https=) |
| CA (1) | CA3043499A1 (https=) |
| MA (1) | MA46972A (https=) |
| MX (1) | MX391156B (https=) |
| WO (1) | WO2018102314A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| EP4093405A1 (en) | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| PE20241579A1 (es) | 2021-09-29 | 2024-08-01 | Ptc Therapeutics Inc | Composicion farmaceutica de sepiapterina |
| CN117117299B (zh) * | 2023-08-14 | 2024-12-06 | 国联汽车动力电池研究院有限责任公司 | 一种无机硫化物固体电解质及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| EP0722731B1 (en) | 1994-08-05 | 2002-06-05 | Suntory Limited | Remedy for spinocerebellar degeneration |
| JP2002515965A (ja) | 1995-08-18 | 2002-05-28 | ダブリュー． ランドリ，ドナルド | 抗体触媒反応の調節による有機化合物の検出 |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007509909A (ja) | 2003-10-31 | 2007-04-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸器疾患の治療のためのｂｈ４の使用 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| EP1687308B1 (en) | 2003-11-17 | 2019-06-12 | Merck & Cie | Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| BRPI0609421B1 (pt) | 2005-04-28 | 2021-06-01 | Shiratori Pharmaceutical Co., Ltd. | Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| LT2545939T (lt) * | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| EA017064B1 (ru) | 2008-03-10 | 2012-09-28 | Такеда Фармасьютикал Компани Лимитед | Кристаллическое производное бензимидазола |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US9884909B2 (en) * | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN104736539B (zh) * | 2012-05-07 | 2017-09-01 | 白鸟制药株式会社 | 墨蝶呤和四氢乳酰蝶呤的制造法 |
| EP3468534A4 (en) | 2016-06-13 | 2020-02-05 | Meharry Medical College | MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH |
| WO2018019931A1 (en) | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| TWI765936B (zh) | 2016-11-29 | 2022-06-01 | 美商東京威力科創Ｆｓｉ股份有限公司 | 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2017
- 2017-11-28 MA MA046972A patent/MA46972A/fr unknown
- 2017-11-28 MX MX2019006207A patent/MX391156B/es unknown
- 2017-11-28 US US16/464,916 patent/US11130760B2/en active Active
- 2017-11-28 EP EP17875641.7A patent/EP3548487A4/en active Pending
- 2017-11-28 WO PCT/US2017/063515 patent/WO2018102314A1/en not_active Ceased
- 2017-11-28 CA CA3043499A patent/CA3043499A1/en active Pending
- 2017-11-28 CN CN201780084819.2A patent/CN110312721A/zh active Pending
- 2017-11-28 JP JP2019548533A patent/JP7148532B2/ja active Active
-
2021
- 2021-09-27 US US17/486,421 patent/US12325706B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500931A5 (https=) | ||
| JP2019535836A5 (https=) | ||
| TWI539951B (zh) | 製備４-｛４-〔（｛〔４-氯-３-（三氯甲基）-苯基〕胺基｝羰基）胺基〕-３-氟苯氧基｝-ｎ-甲基吡啶-２-甲醯胺、其鹽及單水合物之方法 | |
| JP2008543974A (ja) | ペメトレキセド二酸の結晶形およびその調製方法 | |
| WO2015166379A2 (en) | Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts | |
| JP2013523700A (ja) | アミノベンゾフラン誘導体の製造方法 | |
| KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| CN110627791A (zh) | 一种fascaplysin衍生物及制备方法 | |
| WO2017071419A1 (zh) | 洛昔替尼的制备方法 | |
| TW201422594A (zh) | 結晶化合物 | |
| TW201829420A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| WO2009149622A1 (zh) | 6-硝基苯乙酮类化合物、其制备方法及用途 | |
| TW201041855A (en) | New process for preparing | |
| CN103664771B (zh) | 索拉非尼的晶型a及其制备方法 | |
| CN101707952B (zh) | 一种制备利伐斯的明的方法及其中间体 | |
| WO2015075749A1 (en) | Novel processes for the preparation of vemurafenib | |
| CN103288757B (zh) | 6-氨基-7-羟基-3,4-二氢喹唑啉-4-酮的制备方法 | |
| TW201111350A (en) | Process for preparing 2-arylamino or heteroarylamino substituted benzimidazole compounds | |
| AU2010299484A1 (en) | Polymorphs of sorafenib acid addition salts | |
| CN102304078A (zh) | 含乙酰乙酰苯胺类结构的1,4-二氢吡啶类化合物及其制备方法 | |
| IL292206B1 (en) | The salts of a compound and the crystalline forms thereof | |
| JP2010524936A (ja) | トポテカン塩酸塩の結晶形およびその製造方法 | |
| CN106008372A (zh) | 一种达克米替尼的制备方法及其关键中间体 | |
| TWI788141B (zh) | 製備奥希替尼(osimertinib)或其鹽的改良方法 | |
| CN103435559B (zh) | 盐酸厄洛替尼新晶型及其制备方法 |